
样式: 排序: IF: - GO 导出 标记为已读
-
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-18 Tamara J. Bock, Chanukya K. Colonne, Salvatore Fiorenza, Cameron J. Turtle
-
Less-frequent surveillance is noninferior to annual mammography Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-13 Peter Sidaway
Most women with newly diagnosed breast cancer remain alive and recurrence-free for many years after complete surgical resection. Thus, whether all these women require annual follow-up mammography remains uncertain. Now, data from the phase III Mammo-50 trial demonstrate that most women can safely undergo follow-up mammography at 2-yearly or 3-yearly intervals. A total of 5,235 women with previous invasive
-
Artificial intelligence in digital pathology — time for a reality check Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-11 Arpit Aggarwal, Satvika Bharadwaj, Germán Corredor, Tilak Pathak, Sunil Badve, Anant Madabhushi
-
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-10 Rawan G. Faramand, Frederick L. Locke
Recent data from the FELIX trial evaluating obecabtagene autoleucel in patients with relapsed and/or refractory B acute lymphoblastic leukaemia (R/R B-ALL) suggest that this novel intermediate-affinity CD19-directed chimeric antigen receptor (CAR) T cell therapy is associated with a reduced incidence of severe immune-mediated toxicities compared with other commercially available CAR T cell products
-
AI accurately identifies targetable alterations in lung cancer histological images Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-10 Hortense Le, Aristotelis Tsirigos
DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples obtained from patients with lung cancer. This approach provides a cost-effective alternative to genomic testing, generates spatial mutation maps and might support personalized treatment strategies. Validated in diverse datasets, DeepGEM highlights
-
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-07 Diana Romero
Patients with HER2-negative advanced-stage gastric or gastro-oesophageal junction (G/GEJ) adenocarcinomas typically receive chemotherapy with or without an anti-PD-1 antibody as first-line treatment. Now, data from the phase III COMPASSION-15 trial show that combination of the PD-1 × CTLA4 bispecific antibody cadonilimab plus chemotherapy is also efficacious in this setting. In this trial, conduced
-
Transanal TME noninferior to the laparoscopic approach Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-06 Peter Sidaway
Patients with resectable mid–low rectal cancers often undergo total mesorectal excision (TME) surgery. Over the past decade, considerable research interest has been focused on minimally invasive TME procedures that might offer improved perioperative outcomes and preservation of sphincter function, including laparoscopic and transanal approaches. Despite some evidence of an increased risk of local recurrence
-
International approvals of cilta-cel: a lens on CAR T cell regulation Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-06 Chenghao Ge, Chen Yin, Xiaoyuan Chen
The BCMA-targeted chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel (cilta-cel) has demonstrated exceptional efficacy in studies conducted worldwide, which has resulted in regulatory approvals in >40 countries. Herein, we examine the regulatory pathways that led to its approval in different regions, focus on challenges in clinical development and regulatory submission, and provide
-
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-02-03 Jia Luo, Justin A. Bishop, Steven G. DuBois, Glenn J. Hanna, Lynette M. Sholl, Edward B. Stelow, Lester D. R. Thompson, Geoffrey I. Shapiro, Christopher A. French
-
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-31 David Killock
Two multimodal treatment strategies, perioperative chemotherapy and preoperative chemoradiotherapy, have been shown to improve overall survival (OS) compared to surgery alone in patients with locally advanced oesophageal adenocarcinoma (EAC); however, the optimal approach has been unclear. Newly published results from the phase III ESOPEC trial demonstrate the superiority of the perioperative strategy
-
Thermal ablation is safer than resection of colorectal liver lesions Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-30 Diana Romero
Surgical resection is the standard of care for patients with colorectal liver metastases. Thermal ablation has emerged as an alternative management approach for small lesions (≤3 cm diameter), although how it compares with surgery is unclear because most of the available evidence is from meta-analyses of retrospective studies. Now, results from the phase III COLLISION trial demonstrate that thermal
-
Early promising results with addition of an ICI and an anti-angiogenic to TACE Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-27 Diana Romero
Transarterial chemoembolization (TACE) is the standard-of-care treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) who are not candidates for resection, ablation or transplantation, although disease recurrence is common. Now, early data from two phase III trials demonstrate that the addition of both an immune-checkpoint inhibitor (ICI) and an anti-angiogenic agent to TACE
-
Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-27 Branko Cuglievan, Vivek Subbiah
-
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-24 Omar Nadeem, Irene M. Ghobrial
Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple myeloma, which changes the early interception treatment landscape. Herein, we discuss how future studies could build on this success and pave the way to eradicating multiple myeloma before it starts.
-
Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-20 David Killock
Haematopoietic stem cell transplantation (HSCT) and CD19-targeted chimeric antigen receptor (CAR) T cells are potentially curative therapies for relapsed and/or refractory diffuse large B cell lymphoma (R/R DLBCL); however, many patients are unable to receive or have further relapse following these treatments. New data from the phase III ECHELON-3 trial demonstrate the promise of a novel combination
-
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-20 Nicola Normanno, Alessandro Morabito, Anna Maria Rachiglio, Vincenzo Sforza, Lorenza Landi, Emilio Bria, Angelo Delmonte, Federico Cappuzzo, Antonella De Luca
-
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-16 Miguel Lopez de Rodas, Maria Villalba-Esparza, Miguel F. Sanmamed, Lieping Chen, David L. Rimm, Kurt A. Schalper
-
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-06 Yibei Wang, Mohammed Safi, Fred R. Hirsch, Shun Lu, Solange Peters, Ramaswamy Govindan, Rafael Rosell, Keunchil Park, Jianjun J. Zhang
-
Women with clinically node negative breast cancer can safely avoid axillary surgery Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-03 Peter Sidaway
Axillary nodal status provides important information on the prognosis of women with invasive breast cancer. However, the required sentinel lymph node biopsy sampling procedure and the associated risks of surgical complications have raised questions regarding the necessity of this procedure in women undergoing breast-conserving surgery for early stage disease. Now, data from INSEMA, a prospective, randomized
-
Treatment advances across the cervical cancer spectrum Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-03 Alex A. Francoeur, Bradley J. Monk, Krishnansu S. Tewari
-
Imlunestrant shows efficacy both with and without abemaciclib Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-02 David Killock
Various endocrine therapies and CDK4/6 inhibitors have improved the treatment of ER+HER2−breast cancer, although resistance remains common and often involves ESR1 (encoding ERα) mutations. Now, data from the phase III EMBER-3 trial demonstrate that the next-generation, brain-penetrant, oral selective ER degrader imlunestrant delays disease progression in previously treated patients with ESR1 mutations
-
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2025-01-02 David Killock
Sequencing of plasma cell-free DNA (cfDNA) is commonly performed during pregnancy to screen for fetal aneuploidy. Now, data from the ongoing prospective IDENTIFY study demonstrate that this strategy also enables prompt detection of occult maternal cancers. IDENTIFY is enrolling individuals with unusual or nonreportable cfDNA fetal aneuploidy-screening results but without perceived signs or symptoms
-
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-17 Peter Sidaway
Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse. In this
-
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-11 Peter Sidaway
The combination of the anti-PD-1 antibody nivolumab plus the anti-CTLA4 antibody ipilimumab showed promising efficacy outcomes as first-line therapy in 45 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) as part of the single-arm, phase II CheckMate 142 trial. Now, data from the phase III CheckMate 8HW trial confirm the efficacy of this
-
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-10 Maryann Zhao, Jonathan D. Schoenfeld, Ann Marie Egloff, Glenn J. Hanna, Robert I. Haddad, Douglas R. Adkins, Ravindra Uppaluri
-
Leptomeningeal metastatic disease: new frontiers and future directions Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-09 Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz, Stuart A. Grossman, Arjun Sahgal, Emilie Le Rhun, Michael Weller, Tobias Weiss, Tracy T. Batchelor, Patrick Y. Wen, Daphne A. Haas-Kogan, Mustafa Khasraw, Roberta Rudà, Riccardo Soffietti, Philipp Vollmuth, Vivek Subbiah, Chetan Bettegowda, Lily C. Pham, Graeme F. Woodworth, Manmeet S. Ahluwalia, Alireza Mansouri
-
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-03 Tina Cascone, William N. William
As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable NSCLC.
-
Synthetic lethal strategies for the development of cancer therapeutics Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-03 Natalie Y. L. Ngoi, David Gallo, Carlos Torrado, Mirella Nardo, Daniel Durocher, Timothy A. Yap
-
Getting the right combination to break the epigenetic code Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-02 Seda S. Tolu, Aaron D. Viny, Jennifer E. Amengual, Barbara Pro, Susan E. Bates
-
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-29 Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S. W. Tan, Suresh S. Ramalingam, Caicun Zhou
-
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-28 Diana Romero
Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem-cell transplantation (ASCT), although owing to manufacturing and access-related limitations many patients receive rituximab plus gemcitabine–oxaliplatin. Now, data from the phase III STARGLO
-
Minimal residual disease as a target for liquid biopsy in patients with solid tumours Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-28 Klaus Pantel, Catherine Alix-Panabières
-
HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-26 Peter Sidaway
Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting. In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal
-
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-26 David Killock
Many patients with advanced-stage gastric or gastro-oesophageal junction cancer (G/GEJC), particularly those deemed ineligible for combination therapy incorporating antibodies targeting HER2, PD-1 or claudin-18.2, receive chemotherapy alone in the first line. Disease progression typically occurs within a few months and the associated morbidities often preclude standard second-line treatment with ramucirumab
-
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-18 Paolo Ciracì, Vittorio Studiale, Ada Taravella, Carlotta Antoniotti, Chiara Cremolini
-
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-15 Caroline Diorio, David T. Teachey, Stephan A. Grupp
-
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-12 David Killock
Approximately 40% of hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancers harbour activating mutations in PIK3CA (encoding the catalytic subunit of PI3Kα); these mutations are generally associated with a poor prognosis but also responsiveness to inhibitors of the PI3K–AKT pathway. Now, data from the phase III INAVO120 trial demonstrate that addition of the selective PI3Kα inhibitor
-
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-05 Vickie E. Baracos
A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appetite, ingestive behaviour, satiety, nausea and vomiting are starting to move the needle on cancer cachexia. However, clarification of meaningful clinical benefits for patients and the primary end points that should support regulatory approval of cachexia treatments is needed.
-
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-06 Joshua Drago, Shanu Modi
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic hormone-receptor-positive breast cancer, and demonstrated improvements in progression-free survival over standard chemotherapy. These data provide a meaningful advance; however, this strategy might not be right for all patients, and careful consideration is recommended before blanket
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-11-01 Michele D. Stanchina, Skye Montoya, Alexey V. Danilov, Jorge J. Castillo, Alvaro J. Alencar, Julio C. Chavez, Chan Y. Cheah, Carlos Chiattone, Yucai Wang, Meghan Thompson, Paolo Ghia, Justin Taylor, Juan Pablo Alderuccio
-
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-30 Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina
Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-024-00948-1, published online 4 October 2024.
-
Cadonilimab is effective and safe in recurrent cervical cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-25 Diana Romero
The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy with a platinum-based agent and paclitaxel, with or without bevacizumab, and with addition of an anti-PD-1 antibody in those with a PD-L1 combined positive score (CPS) ≥1. Now, data from the phase III COMPASSION-16 trial show that addition of the PD-1 × CTLA4 bispecific antibody
-
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3 Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-25 Zev A. Wainberg, Eileen M. O’Reilly
We read with interest the News & Views article by Nevala-Plagemann and Garrido-Laguna (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))1. In this article, the authors question whether the addition of nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) to therapeutic options
-
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’ Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-25 Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
We appreciate the interest of Wainberg and O’Reilly in our recently published News & Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))1. In their Correspondence (Wainberg, Z. A. & O’Reilly, E. M. NALIRIFOX in the
-
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-23 Diana Romero
Patients with muscle-invasive bladder cancer (MIBC) typically undergo radical cystectomy with bilateral pelvic lymphadenectomy to achieve local disease control and identify pathological nodal metastases. The optimal extent of lymphadenectomy remains a matter of debate and many centres favour an extended approach, despite a lack of evidence from randomized trials. Now, results from the phase III SWOG
-
The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-21 Brian Badgwell
Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compared with surgery alone. Now, data from the TOPGEAR trial demonstrate that adding radiotherapy to standard-of-care perioperative chemotherapy offers no additional survival benefit. I discuss the implications for treatment and future research.
-
MRI-based stratification reduces the risk of overdiagnosis of prostate cancer Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-16 Peter Sidaway
Men with a serum PSA of >3.0 ng/ml are typically referred for further diagnostic investigations for prostate cancer; however, many either will not have the disease or will have low-risk tumours and might have adverse events from unnecessary diagnostic procedures and/or overtreatment. Now, an update from the ongoing GÖTEBORG-2 study demonstrates that men without suspicious lesions detected on MRI of
-
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-07 Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary W. Middleton, Sabine Tejpar
Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-024-00943-6, published online 24 September 2024.
-
The high costs of anticancer therapies in the USA: challenges, opportunities and progress Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-04 Shelley A. Jazowski, Rahul K. Nayak, Stacie B. Dusetzina
-
Reflecting on the past 20 years in oncology Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-01
The November 2024 issue of Nature Reviews Clinical Oncology marks the 20th anniversary of the journal. Here, we reflect on the role of the journal during a time in which the clinical oncology community has witnessed many important changes.
-
Two decades of advances in clinical oncology — lessons learned and future directions Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-10-01 Susana Banerjee, Christopher M. Booth, Eduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry, Irene M. Ghobrial, Luca Gianni, Rakesh K. Jain, Guido Kroemer, Josep M. Llovet, Georgina V. Long, Klaus Pantel, Kathy Pritchard-Jones, Howard I. Scher, Josep Tabernero, Ralph R. Weichselbaum, Michael Weller, Yi-Long Wu
Since the publication of the first issue of Nature Reviews Clinical Oncology, we have witnessed advances in multiple research areas that have culminated in improved outcomes for many cancer types, although substantial unmet needs remain for a majority of patients worldwide. Here, we have asked experts in several key specialities to reflect on the progress from the past 20 years and propose the next
-
From the ESMO Congress 2024 Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-30 David Killock
For a second consecutive year, members of the oncology community recently descended on Spain to hear the practice-changing results and latest advances in clinical cancer research presented at the annual ESMO Congress. As in Madrid last year, this year’s meeting in Barcelona was attended in person or online by more than 30,000 delegates, from 149 countries. Multiple phase III trials featured in the
-
Molecular imaging supports the development of multispecific cancer antibodies Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-26 Claudia A. J. van Winkel, Frank R. Pierik, Adrienne H. Brouwers, Derk Jan A. de Groot, Elisabeth G. E. de Vries, Marjolijn N. Lub-de Hooge
-
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-26 Diana Romero
Eligible patients with muscle-invasive bladder cancer (MIBC) typically receive cisplatin-based chemotherapy before radical cystectomy, although approximately 50% will have disease relapse within 3 years. Now, newly published data from the phase III NIAGARA trial simultaneously presented at the ESMO Congress 2024 demonstrate that adding perioperative durvalumab to neoadjuvant chemotherapy improves outcomes
-
CABINET presents cabozantinib as a new treatment option for NETs Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-24 David Killock
Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting. In CABINET, patients with locally advanced or metastatic well or moderately
-
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-24 Christopher J. M. Williams, Allyson M. Peddle, Pashtoon M. Kasi, Jenny F. Seligmann, Campbell S. Roxburgh, Gary M. Middleton, Sabine Tejpar
-
A new standard of care for leiomyosarcoma Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-19 Peter Sidaway
Patients with advanced-stage leiomyosarcoma, a type of soft-tissue sarcoma that occurs predominantly in uterine locations, typically receive doxorubicin and have a median overall survival (OS) of ~20 months. Now, data from a randomized phase III trial demonstrate that adding trabectedin to doxorubicin significantly improves OS. A total of 150 patients with previously untreated locally advanced or metastatic
-
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-13 Adrienne G. Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara M. Tolaney, Aleix Prat
-
Vorasidenib: a new hope or a false promise for patients with low-grade glioma? Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-12 Stanislav Lazarev, Kunal K. Sindhu
Despite recent FDA approval, the clinical utility of vorasidenib in the treatment of IDH-mutant low-grade gliomas remains unclear. Herein, we critique the pivotal trial of vorasidenib, and highlight the questionable choice of control intervention and end points, ethical concerns, as well as the uncertain efficacy observed, and argue that the approval might be premature given the high cost of this drug
-
New clinical trials in CUP and a novel paradigm in cancer classification Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-09-11 Elie Rassy, Fabrice André